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Methylphenidate vs. amphetamine: Comparative review 
L.E. Arnold 
This article compares the two most common medications for Attention-Deficit/Hyperactivity Disorder 
(ADHD), using data from controlled studies. Medline and Psychinfo searches were done for 1984-1996 with 
the key words methylphenidate (MPH) and amphetamine (AMP); these were supplemented with known prior 
and recent literature. Of 92 animal studies found, 15 showed clear differences between the two drugs. Ten 
reports of controlled crossover ADHD clinical trials (three in the same sample) and a dozen other articles 
comparing the two drugs in humans were found. MPH is a pure re-uptake inhibitor of catecholamines, 
especially dopamine; AMP also releases catecholamines. Lab animals showed differential interactions with 
other drugs and with behavioral paradigms. Human response profiles are noncongruent. An ADHD patient 
who fails on one stimulant should try the other. Of 174 patients in the 6 clearest crossover studies, 48 
responded better to AMP, 27 to MPH, and at least 72 to both, which is an 87+% overall response rate if both 
are tried. All crossovers, except the one with comorbid Tourette's, showed a nonsignificant tendency for 
AMP superiority in response rate. Summed data suggest suspected differences in side effects (AMP more 
sleep and appetite loss and exacerbation of tics in comorbid Tourette's, MPH possibly more 
depression/apathy and stomachaches) and effects on comorbid disorders (AMP better for 
conduct/oppositional symptoms, MPH for Tourette's and possibly learning disorder (LD). Most of the 
clinical differences are tendencies rather than statistically significant. 
Methylphenidate (MPH, e.g., Ritalin®) and amphetamine (AMP), especially its dextro- 
isomer dextroamphetamine (e.g., Dexedrine®, Dextrostat®) and, more recently, a mixture of 
amphetamine salts marketed as Adderall®, have been respectively the most commonly used and 
second most commonly used drugs for treatment of Attention-Deficit/Hyperactivity Disorder 
(ADHD). Although they are more similar than different in their pharmacodynamics and clinical 
effects, there are subtle differences that can be important at the level of the individual patient, if not 
in group data. This article will review animal and human data to reach a better understanding of the 
differences and their potential clinical application. In addition to the author's knowledge of the 
literature, a computerized literature search through Medline and Psychinfo was done for the years 
1984-1996. 
Although the subjective effects of MPH and AMP are similar (Heishman & Henningfield, 
1991), neurochemical effects of the two stimulants are distinct (Little, 1993), with different 
mechanisms of action (Glavin, 1985). Methylphenidate is a "pure uptake inhibitor" (Heron, 
Costentin, & Bonnet, 1994) without other presynaptic activity, while amphetamine has additional 
presynaptic activity (Hess, Collins, & Wilson, 1996), releasing dopamine (DA) and 
norepinephrine (NE) from the presynaptic neuron (e.g., During, Bean, & Roth, 1992). Also, AMP 
has a slightly longer plasma half-life: 4-6 hours compared to 2-3 hours for MPH (e.g., Barkley, 
DuPaul, & Costello, 1993). A significant proportion of AMP is directly excreted in the urine 
(especially acidic urine), while MPH is completely metabolized: 80% to inactive molecules 
(Barkley et al, 1993), though 20% is hepatically metabolized to parahydroxy-MPH, an active 
metabolite. AMP, but not MPH, lowers plasma and urinary 3-methoxy-4-hydroxyphenylglycol 
(MHPG) and norepinephrine (NE) turnover, while MPH, but not AMP, increases plasma NE (Elia, 
Borcherding, Potter, Mefford, Rapoport, & Keysor, 1990). Presumably resulting from the subtle 
difference in mechanism of action, there are also behavioral and drug interaction differences in 
laboratory paradigms and individual patient variation in clinical response. These are reviewed and 
documented below. 
Animal Comparisons 
Table 1 (overleaf) summarizes the 15 reports found on animal research since 1984 that 
showed clear differences between MPH and AMP. Differences may have shown up in other 
laboratory studies, but were not reported clearly enough to suit the purposes of this review. Of the 
92 articles reviewed, most did not report any differences in the effects of the two drugs. In fact, 
most laboratory studies that included both drugs were not focused on comparing them, but 
included them as probes to study some other issue; the differences found were, in many cases, 
unexpected. Many of the differences were significant at levels better than 0.05, making a Type I 
error unlikely despite the low proportion of studies finding differences — except for the case of an 
apparent contradiction. While Svensson, Hohansson, Magnusson, and Carlsson (1986) found that 
reserpine pretreatment prevented MPH-induced, but not AMP-induced, locomotor hyperactivity, 
Finn, Iuvone, and Holtzman (1990) found almost the reverse: reserpine pretreatment attenuated 
locomotor hyperactivity induced by AMP, but not that induced by MPH. The apparent 
contradiction is not explained by species difference because both investigators used rats. However, 
they could have been different strains (not specified). Another possible difference in technique 
was that Svensson et al. used habituated animals. 
Reserpine, of course, has serotonin-blocking activity, supporting putative interaction 
between the serotonin and catecholamine (dopamine, norepinephrine) systems. If reserpine 
pretreatment does indeed differentially modify the effects of the two stimulants, this could have 
implications for polypharmacy with a stimulant and one of the newer, atypical neuroleptics with 
serotonin activity, and possibly even with a stimulant and a serotonin-reuptake inhibiting 
antidepressant. For example, if a given modern serotonin-active drug mimics the reserpine 
interaction found by Svensson et al. (1986), it might interfere with the therapeutic effect of MPH 
but not AMP; conversely, if it has the opposite effect of reserpine, it might potentiate MPH benefit 
but not AMP. On the other hand, if Finn et al. (1990) are correct, these theoretical considerations 
could be reversed. All this, of course, assumes extrapolation from rats to humans, not always a 
valid exercise. 
Other possible differential drug interactions are suggested by the animal literature. One 
arises from the fact that haloperidol blocked place preferences that were induced by AMP, but not 
those induced by MPH (Mithani, Martin-Iverson, Phillips, & Fibiger, 1986). (The combination of 
haloperidol and a stimulant is sometimes used in treatment of comorbid Tourette's and ADHD or 
comorbid bipolar disorder and ADHD.) To my knowledge, there are no controlled studies 
comparing the clinical effects of the two stimulants in the presence of haloperidol or other 
neuroleptics. 
It is not clear what we should make of the finding of Hess et al. (1996) in naturally 
hyperactive Coloboma mice, where AMP reduced, but MPH increased, activity. Since MPH 
decreases activity in most naturally hyperactive humans, the mice must be hyperactive through a 
different mechanism than most humans. Study of that difference might illuminate not only 
mechanisms of stimulant action but also pathogenetic mechanisms and subtypes of ADHD. It is 
conceivable, of course, that the hyperactive Coloboma mice suffer the same pathogenetic 
mechanism as the minority of hyperactive humans who respond to AMP but not MPH. 
Human Comparisons Other Than ADHD Clinical Trials 
Table 2 (overleaf) summarizes the 6 reports found comparing MPH and AMP in human 
studies other than ADHD clinical trials. Interestingly, Little (1993) reported the same situation in 
treating depression, as we will see below with treatment of ADHD: 2/3 efficacy for either drug, 
with only partial overlap of efficacy and no way of predicting which will be better for a given 
patient. 
Parallel and Uncontrolled Comparisons in Treatment of ADHD 
Before examining the controlled crossover comparisons of MPH and AMP for treatment of 
ADHD, it is worth noting seven other relevant reports ranging from placebo-controlled 
parallel-group comparisons to naturalistic chart reviews:
Reference Isomer1 Effects Studied Findings
Moss, Koob, McMaster, 
& Janowsky (1984) 
dl behavioral Tetrahydrocannabinol pretreatment doubled AMP-induced gnawing without 
affecting AMP locomotor activity, but suppressed MPH-induced locomotor 
activity without affecting MPH-induced gnawing. 
Mithani et al.(1986) dl behavioral Haloperidol pre-treatment blocked place preferences induced by AMP, but not 
those induced by MPH. 
Rosen et al. (1986) dl behavioral Under high-AMP-dose discriminative stimulus training, MPH, but not AMP, 
generalization gradient was different for lead-exposed and control rats. 
Svensson et al. (1986) dextro behavioral Reserpine pre-treatment completely prevented MPH-induced, but not 
AMP-induced, locomotor hyperactivity. 
Holtzman(1986) dextro behavioral In rat discrimination experiments, MPH generalized completely, but AMP only 
partially, with caffeine. 
Sershen, Berger, 
Jacobson, et al. (1988) 
dl behavioral Metaphit, a phencyclidine analog, antagonized the locomotor stimulation induced 
by MPH, but not that induced by AMP. 
Zetterstrom, Sharp, & 
Collin (1988) 
dl biochemical AMP, but not MPH, decreases striatal extracellular 3,4-dihydroxyphenylacetic 
acid (DOPAC), a metabolite of DA2. 
Logan, Seale, Cao, & 
Carney (1988) 
dextro behavioral In BALB/cByJ mice, AMP up to 10 mg/kg acutely had no effect or inhibited 
locomotor activity (LA); MPH 10-32 mg/kg acutely stimulated LA. After 21 days 
AMP 10 mg/kg, 3.2 mg/kg stimulated LA (no longer inhibited), and MPH no 
effect in doses that had acutely stimulated. 
Zaczek et al. (1989) citation of dl biochemical MPH (and pemoline) did not induce the decrease in brain monoamine markers 
found with methamphetamine and previously with AMP. 
Finn, luvone, & 
Holtzman(1990) 
dextro behavioral Pretreatment with reserpine or alpha-methyl-para-tyrosine attenuated the increase 
of locomotion induced by AMP or caffeine, but not that by MPH. 
Nomikos, Damsma, & 
Wenkstern(1990) 
dextro biochemical Tetrodotoxin, which blocks voltage-dependent Na+ channels, prevented 
MPH-induced, but not AMP-induced, increase in extracellular DA. 
During, Bean, & Roth 
(1992) 
dl biochemical MPH released DA and neurotensin co-synchronously from rat prefrontal cortex; 
but with AMP, neurotensin release lagged behind DA release. 
McNamara, Davidson, 
&Schenck(1993) 
dl behavioral Chronic administration of AMP sensitizes; chronic MPH develops tolerance. 
(Repeated doses of AMP over 7-day period augment the usual response of 
increased activity; repeated MPH decreases the subsequent responses.) 
Jones & Holtzman (1994) dextro 
& levo 
behavioral Naloxone attenuated gross (though not fine) HA3 induced by both amphetamine 
isomers, but not HA induced by MPH. 
Heron, Costentin, & 
Bonnet (1994) 
dextro biochemical MPH binds slowly to DA neuronal carrier; AMP interacts rapidly with DA 
neuronal carrier. 
Wall, Gu, & 
Rudnick(1995) 
dl biochemical AMP caused efflux of DA & NE4 across respective transporters in cell culture; 
MPH did not. Both inhibited influx. 
Hess, Collins, & Wilson 
(1996) 
dl behavioral AMP reduced activity in naturally HA Coloboma mice, increased in controls; 
MPH increased activity in both. 
1Isomer = the form of amphetamine (AMP) that was compared to methylphenidate (MPH); dextro = d-amphetamine; levo = l-amphetamine; dl = racemic 
amphetamine 
2DA = dopamine 3HA = hyperactivity 4NE = norepinephrine 
Table 1 Some animal research comparing methylphenidate (MPH) and amphetamine (AMP) 
Reference AMP Isomer1 Type of Study, N Dose Finding
Lieberman, Kane, & 
Alvir (1987) 
dl, dextro? Clinical; review of 
36 studies 
variable In challenges with schizophrenic patients, MPH appears to have greater 
psychotogenic potency than AMP. 
Little (1988) (Review 
article)2 
dl, dextro Clinical; review of 5 
studies; adults 
variable In depression, 85% of AMP responders but only 43% of AMP nonresponders
improve with antidepressant Tx; MPH resprs & nonresprs improve equally. 
Elia et al. (1990) dextro Biochemical; blind 
crossover; 31 
children 
AMP 1.5 mg/ 
kg/d; MPH 
3.0 mg/kg/d 
AMP but not MPH lowered plasma/urinary MHPG, NE turnover; MPH but 
not AMP raised plasma NE. 
Little (1993) dextro Clinical; blind 
crossover; 12 M, 8 F; 
24-45 yr 
MPH 40 mg; 
AMP 20 mg; 
test doses 
17/18 depressed inpatients improved acutely after AMP or MPH, but only 
5/18 showed equal improvement to both. 7 responded only to AMP, 5 only to 
MPH. Which was better was unpredictable, with no drug-specific target Sx. 
Little et al. (1993) dl Biochemical 
postmortem in vitro 
homogenized 
membrane 
MPH binds more strongly, but AMP more weakly, than cocaine or bupropion
to binding sites of [125l]RTI-55, a cocaine congener. 
Matochik et al. 
(1994) 
dextro Biochemical; PET 
scans before and 
after 6 wk MPH 
(n=19)or AMP (n 
=18); adults 
MPH 5-25 
mg b.i.d.; 
AMP 5-15 
mg b.i.d. 
MPH changed metabolism in 2 of 60 brain regions sampled by PET; AMP did 
not change metabolism in any region (adult Ss with ADHD). With randomly 
assigned noncrossover Tx, CGI= 2.1 for MPH, 1.9 for AMP (lower score 
better but not significantly different); Conners change scores = 11.6 and 9.1 
for MPH, 10.6 and 7.3 for AMP (n.s.). On 2 other scales, MPH significantly 
improved 11/60 feelings/symptoms, AMP 19/60, only 7 in common. Ratings 
nonblind. 
All drug administration was by mouth except the in vitro study (Little et al., 1993). 
11somer = the form of amphetamine (AMP) that was compared to methylphenidate (MPH); dextro = d-amphetamine; levo = l-amphetamine; dl = racemic 
amphetamine. 
2The 1988 Little review was challenged by Gwirtsman and Guze (1989), who argued that MPH response predicted antidepressant response to an 
adrenergic TCA, while MPH nonresponse predicted response to a serotonergic TCA. 
Table 2 Some human comparisons of methylphenidate and amphetamine other than ADHD clinical trials 
1. Millichap and Fowler (1967) reviewed the available literature, consisting of one-drug 
studies in different samples, some not well controlled. After averaging the response rate across 
studies for each drug (with response defined differently from study to study, even using different 
instruments), they found a higher mean response rate for MPH and concluded that it is "the drug of 
choice." Arnold and Knopp (1973) pointed out that this conclusion was not based on any 
controlled direct comparison of MPH and AMP in the same sample, but it persists to the present as 
clinical belief in some circles despite the fact that the only one of the subsequent controlled 
crossover comparisons in Table 3 (overleaf) that supports it is the one in comorbid Tourette's 
(Castellanos et al., 1997). 
2. Weiss, Minde, and Douglas (1971) compared the results of chlorpromazine, MPH, and 
d-AMP from three different samples studied in three different years. They believed that MPH was 
slightly more efficacious with about the same side effects. 
3. Conners (1972) came closer to a valid comparison, studying both stimulants in the same 
sample, but unfortunately with a parallel pretest-posttest design so that individual subject variables 
were not well controlled. He randomly assigned 70 boys and 5 girls age 6-12 to 6 weeks of placebo 
(n =22), MPH (n =29), or d-AMP (n =24). Doses were individually titrated weekly to a cap of 30 
mg MPH or 15 mg d-AMP daily in divided doses (morning and noon). Titration started at 1/3 the 
cap dose. 
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a drug effect, thus artificially depressing the response rates. The upper number of the ranges is 
calculated by excluding those two studies. These ranges are lower-bound estimates (see text). 
Table 3 Controlled crossover comparisons of methylphenidate (MPH) and amphetamine (AMP) in ADHD 
and its historical precursors1
Both drugs were better than placebo on multiple measures. MPH showed an advantage over 
d-AMP on the arithmetic and similarities subtests of the Wechsler Intelligence Scale for Children, 
but not on other subtests, tests, or scales in a reasonably comprehensive assessment battery. Both 
drugs showed more insomnia and anorexia than placebo; in fact, d-AMP showed more than MPH, 
but few of the side effects were moderate or severe. 
4. Swanson et al. (1998) reported a comparison of MPH and Adderall®, a mix of 
amphetamine salts containing 3/4 d-amphetamine and 1/4 1-amphetamine. Though it was a 
double-blind placebo-controlled crossover study with random assignment to order, it is not listed 
in Table 3 because the design and dosing did not lend themselves to the efficacy and side effects 
comparisons made in the table. Thirty-three MPH responders with DSM-IV ADHD were assigned 
in random order to a week each of their established effective MPH dose (5-20 mg), placebo, and 5, 
10, 15, and 20 mg Adderall® (6 conditions total), all given once each morning of the respective 
week, including at a Saturday analogue school. The focus of the study was duration of effect. Both 
drugs significantly benefited behavioral symptoms and academic productivity compared to 
placebo. MPH reached peak effect earlier and wore off earlier than all but the smallest Adderall® 
dose. Duration of MPH effect averaged about 4 hours, with duration of Adderall® effect up to 6.4 
hours at the 20-mg dose. 
5. Manos, Short, and Findling (1999), in a nonrandomized but otherwise well-done parallel 
placebo-controlled design, compared 42 subjects age 5-17 taking Adderall® to 42 matched 
subjects taking MPH (selected out of 117 subjects in the MPH protocol). The choice of active drug 
was by the patient's physician, but titration was double-blind placebo-controlled. Fifteen of the 
Adderall® patients had previously failed a MPH trial. In this trial, no significant differences 
between the two active drugs were found, with both significantly improving parent and teacher 
ratings of behavior. The "best dose" blindly identified ranged from 5-15 mg, q a.m. for Adderall® 
and b.i.d. for MPH. A single morning dose of Adderall® seemed as effective as b.i.d. MPH. 
6. In a retrospective chart review of prospectively collected data on 200 private patients, 
Grcevich, Rowane, Marcellino, and Sullivan-Hurst (1999) found that 75% of MPH patients were 
dosed t.i.d. or more often, while 89% of Adderall® patients were dosed b.i.d. or less. A survival 
curve showed an impressive difference in length of time on the first drug tried, with 25% switching 
from MPH to another drug after 2 months but only about 10% switching from Adderall® after 5 
months. 
7. In a double-blind design, Pliszka, Browne, Wynne, and Olvera (1999) randomly 
assigned 58 children to placebo, a MPH dosing algorithm, or an Adderall® dosing algorithm. Both 
algorithms started with a morning dose of 10 mg, then (if indicated) increased this and/or added a 
noon and/or afternoon dose as indicated by feedback about behavior and performance at various 
times of day. Both active drugs were significantly better than placebo, but the slight Adderall® 
advantage over MPH was not statistically significant. Of note, 70% of Adderall® patients, but 
only 15% of MPH patients, could be satisfactorily maintained on once-a-day dosing. 
Controlled Crossover Comparisons in Treatment of ADHD 
Table 3 summarizes the 10 reports of controlled crossover comparisons found. These 
actually represent only 8 independent samples because the large samples of Borcherding, Keysor, 
Rapoport, Elia, and Amass (1990), Elia, Borcherding, Rapoport, and Keysor (1991), and 
Castellanos, Gullota, and Rapoport (1992) overlapped. Uncontrolled or noncrossover comparisons 
of MPH and AMP are not tabulated here (see preceding section). 
In examining Table 3, we need to remember that most group mean differences between the 
two stimulants are not significant because of the small samples, so that we are essentially studying 
nonsignificant subtle trends. Within this constraint, it seems appropriate to note some themes. The 
most obvious is that no study shows congruence in response at the individual subject level. That is, 
every study has some subjects who responded to one drug but not the other. In most studies, this is 
a two-way street: some respond better to MPH, others better to AMP. 
Another noteworthy theme is that every crossover study except the one in comorbid 
Tourette's (Castellanos et al., 1997) shows a slight (nonsignificant) advantage for AMP in the 
number of individuals judged responsive or in the number judged to have a better response than to 
the other active condition(s). The references do not use strictly comparable reporting methods: for 
example, Winsberg, Press, Bialer, and Kupietz (1974) and Elia et al. (1991) report response or 
nonresponse in a binary fashion, while Arnold, Christopher, Huestis, and Smeltzer (1978) and 
Pelham et al. (1990, 1999) report which is better or clinically preferable for maintenance, even 
where both are efficacious. Castellanos et al. (1992) reported only those better with AMP and not 
those better with MPH, presumably 35 or less, since there were at least 2 nonresponders in that 
sample (reported by Elia et al., 1991 in the first 48 Ss). Nevertheless, since both drugs are reported 
the same way within a given study for each of the other 8 studies, it seems permissible to sum them 
for comparison. 
Summary of Responders 
Of the 222 subjects in the 8 nonduplicative studies in Table 3 (Arnold et al., 1978; 
Castellanos et al., 1997; Elia et al, 1991; Pelham et al, 1990, 1999; Sharp et al, 1999; Winsberg et 
al, 1974; Vyborova, Nahunek, Drtilkova, Balastikova, & Misurec, 1984), 63 responded better to 
AMP and 38 better to MPH. If we eliminate the study of Vyborova et al. because of the 
noncomparable dosing and the contradiction between response rate and mean global score, and 
eliminate the study of Castellanos et al. (1997) because of the focus on relatively rare comorbidity 
(Tourette's), the totals are 48 AMP and 27 MPH in the remaining 6 studies. If we add the 72 known 
double responders (there may have been more undetected by the reporting methods) to each total, 
there were 120 (or more) AMP responders vs. 99 (or more) MPH responders in these 6 studies, 
with 174 subjects and 22 nonresponders. This translates to a 69+% response rate for AMP and 
57+% for MPH, with an 87+% stimulant response rate if both are tried. 
This overall response rate of 87% should be considered a lower bound estimate because it 
was skewed by the high "nonresponse" rate in the two studies of Pelham et al, in which the subjects 
were children in an intense full-time summer behavioral treatment program, which normalized 
behavior on placebo, eliminating the variance needed to detect drug effect. Excluding the two 
studies of Pelham et al. yields a response rate of 92% for trying both drugs (68% for MPH, 77% for 
AMP). The response rates by individual drug (69-77% AMP, 57-68% MPH) should be considered 
lower bound estimates because the reporting method for some studies left some double responders 
undetected. 
Relative Strengths 
Beyond the global response, finer-grained scrutiny of effects on specific symptoms 
suggests some subtle differences. Some of these relate to comorbidity. Castellanos et al. (1997), of 
course, found MPH better in the presence of comorbid Tourette's. In several of the studies, AMP 
seemed to have a greater effect on such oppositional-defiant and conduct-disorder (ODD/CD) 
symptoms as aggression (with effect size [E.S.], Cohen's d, of 0.16, 0.25, and 0.45), irritability 
(E.S.=0.19), explosiveness (E.S.=0.15), noncompliance (E.S.=0.35), negative verbalization 
(E.S.=0.24), rule-breaking (E.S. =0.25), and Iowa Conners O/D rating (E.S.=0.3, p <0.01 by 
counselors). Most of these were nonsignificant, of course, at the sample sizes studied. In no study 
did MPH show a tendency of superiority on such symptoms. On the other hand, AMP did not show 
an impressive advantage on inattention symptoms, even though Pelham et al. (1999) found the 
AMP advantage significant on counselor (p <0.001) and parent (p <0.05) ratings of 
inattention/overactivity. The study (Winsberg et al, 1974) that found an E.S. of 0.45 for AMP 
superiority on aggression found an E.S. of only 0.14 for AMP superiority on inattention. The study 
(Arnold et al, 1978) that found an E.S. of 0.25 for teacher rating of aggression found only 
E.S.=0.02 and 0.14 for teacher ratings of inattention on 2 different scales. The advantage of MPH 
on the Conners Continuous Performance Test (CPT) reported by Elia et al. (1991) may be related 
to the report of Vyborova et al. that MPH preferentially helped patients with visuo-motor 
disorders. If the suggestive trends noted here were upheld by further study, it could lead to a 
preference for MPH in ADHD comorbid with Tourette's or learning disorder (LD) and for AMP in 
ADHD comorbid with ODD/CD. 
One of the few statistically significant differences reported was that AMP showed a more 
consistent response day-to-day, with less within-subject variability (Pelham, 1991). The 
significant association of AMP superiority with high IQ (Castellanos et al, 1992) was one of the 
more exciting differences found. It offered hope of a simple clinical predictor of which stimulant 
should be tried first in a given case. It also articulated neatly with the report of Vyborova et al. that 
MPH was better for children with visuo-motor disorder and AMP better for those without; both 
findings could be accommodated by a hypothesis that AMP worked better for those without 
cognitive handicap and MPH better for those with handicap or low functional level. Unfortunately, 
this finding (association with IQ) was not replicated in a prospective study (F.X. Castellanos, 
personal communication). 
Side Effects 
Side effects were, in general, similar with both drugs. For example, Winsberg et al. (1974) 
reported 6 (of 18 Ss) had side effects with each drug, while Elia et al. (1991) reported that 37 (of 48 
Ss) had side effects with MPH and 35 with AMP. Within this context of similarity, there were 
some subtle trends and tendencies (mostly nonsignificant). Five studies, with 156 Ss, found more 
anorexia with AMP compared to no study finding more anorexia with MPH. Five studies, with 114 
Ss, found more sleep delay with AMP compared to none finding more with MPH. Three studies, 
with 88 Ss, found more apathy/tear-fulness/unhappiness with MPH compared to two studies, with 
47 Ss, finding more sadness/withdrawal/listlessness with AMP. Castellanos et al. (1997) found 
more exacerbation of tics with AMP than with MPH in patients comorbid for Tourette's disorder. 
Clinical Implications and Discussion 
Table 4 summarizes the relative advantages of MPH and AMP for treatment of ADHD, as 
suggested by the foregoing review and supplementary clinical experience. Many of the differences 
listed do not reach statistical significance. Although very similar in many ways, the two stimulants 
are in some ways complementary in patient responsiveness. The clearest lesson gleaned from the 
controlled studies is that the individual patient response profiles are noncongruent, and that 
nonresponse or intolerable side effects with one stimulant does not preclude a good response to the 
other. Interestingly, Little (1993) could have been talking about ADHD when he said this about 
MPH and AMP for depression: "Relatively few responded with equal improvement to both ... 
symptomatic improvement is unpredictable and can only be determined by an empirical trial on an 
individual basis." Therefore, each should be tried before giving up on stimulant treatment, and 
patients and parents should be forewarned of this. 
While this review found no evidence to make MPH the drug of choice for ADHD in 
comparison to other stimulants, this does not detract from the fact that stimulants as a class 
constitute the drugs of choice. One can fill in where another fails, so that together they can help the 
vast majority of patients with ADHD. Possibly the response rate with trials of both MPH and AMP 
could be increased even further with a third stimulant: Pelham et al. (1990) reported that four of 
their 22 patients did best with pemoline. The advantage of trying both MPH and AMP has public 
policy implications: the bureaucratic Medicaid obstacles to AMP prescriptions in some states may 
be depriving some Medicaid ADHD children of their best treatment. 
Beyond the basic principle of systematically trying a second stimulant if the first fails, 
there are some hints in Table 4 that might guide the choice of which stimulant to try first. For 
example, a child who already has a poor appetite might do better with MPH, while one prone to 
stomachaches might do better with AMP. If the child has a history of seizures and is not currently 
taking an anticonvulsant, AMP may be slightly safer. The type of comorbidity may be a 
consideration: a child with either Tourette's disorder or LD and with no conduct or 
oppositional-defiant (CD/ODD) symptoms might try MPH first, while one with CD/ODD and no 
LD or Tourette's might try AMP first. This is not to say that either stimulant would not help the 
other comorbidity or that either is guaranteed to help its favored comorbidity, but in the absence of 
any more compelling reason for choosing the first trial drug, why not follow the hint suggested by 
the literature review? 
Chiral Pharmacology 
This review has not addressed the issue of stereo-iso-mers, which may also have subtle 
differential effects in individual patients. Five decades ago Bradley (1950) noted that some 
hyperkinetic children responded better to racemic amphetamine, while others responded better to 
the dextro isomer. MPH has four stereo-isomers: the erythro- and threo- forms each have a dextro- 
and levo-isomer. The commercially available MPH (Ritalin®) is a racemic (dl) mixture of the 
threo- enantiomer (however, dextro-threo-MPH is currently being developed for market). The 
most popular form of amphetamine has long been the dextro- isomer (Dexedrine® or 
Dextrostat®), which was used in most of the clinical studies in Table 3 and constitutes most of the 
basis for the comparison with MPH in Table 4. Arnold et al. (1973, 1976) found that 
levo-amphetamine has clinical benefits in ADHD comparable on group data to the dextro-isomer, 
and reported that a few patients responded to one isomer but not the other. They also suspected 
some subtle tendencies for different side effects and even different clinical benefit by comorbidity. 
Further, the effect of the two isomers on visual-motor function was significantly different (Arnold, 
Huestis, Wemmer, & Smeltzer, 1978). Adderall® is 3/4 dextroamphetamine and 1/4 
levoamphetamine, with anecdotal claims that a few children with ADHD respond better to this 
mix than to straight dextroamphetamine. It 
Advantages of MPH Advantages of AMP
Better CPT responsea More consistent response day-to-daya 
Better with comorbid Tourette'sa Higher proportion of patients with good/excellent response*3 
Better with visuo-motor disorderC Better with comorbid CD/ODDb 
Possibly better with comorbid LDC May be better with high IQd 
Less anorexia, less weight lossb Less depression/apathyc 
Less sleep delayb Fewer stomachachesc 
Less temporary growth suppression in low dosesc Safer when history of seizuresc; slightly anticonvulsant in low dosesb 
Lower street value and abuse potential Usually cheaper legally (generic) 
Variety of regular tablet strengths: 5,10,20 mg* Variety of SR Spansule strengths (5,10,15 mg); SR seems more 
More readily available to Medicaid patients consistently efficacious than SR MPH 
 Longer half-life and clinical effect 
Few of these reach statistical significance; most are tendencies noted in more than one report in literature 
review. 
aStatistically significant in a controlled study 
bProbable 
cPossible, suggested 
dSignificant in post hoc analysis of controlled study but not replicated in prospective study 
*Dextro-threo-methylphenidate, when available, may be marketed in 2.5 mg as well as 5 and 10 mg 
Table 4 Relative advantages of methylphenidate (MPH) and amphetamine (AMP) for treatment of ADHD 
was the form of AMP used by Pelham et al. in their 1999 study (Table 3), which showed statistical 
superiority of MPH by counselor ratings. On the assumption that stimulants as a class will 
continue to be the drugs of choice for treatment of ADHD, clinical science could benefit from 
more systematically controlled comparisons of the various isomers, and combinations thereof, of 
both these drugs. Such studies would require rather large samples in order to analyze for all the 
patient characteristics that might influence the choice of stimulant (e.g., age, sex, comorbidity, 
physical habitus). 
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